The use of bevacizumab and ranibizumab for branch retinal vein occlusion in medicare beneficiaries.

about

The use of bevacizumab and ranibizumab for branch retinal vein occlusion in medicare beneficiaries.

Item

http://www.wikidata.org/entity/Q55551050

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

The use of bevacizumab and ran ...... ion in medicare beneficiaries.

@en

The use of bevacizumab and ran ...... ion in medicare beneficiaries.

@nl

type

Item

label

The use of bevacizumab and ran ...... ion in medicare beneficiaries.

@en

The use of bevacizumab and ran ...... ion in medicare beneficiaries.

@nl

prefLabel

The use of bevacizumab and ran ...... ion in medicare beneficiaries.

@en

The use of bevacizumab and ran ...... ion in medicare beneficiaries.

@nl

P1476

The use of bevacizumab and ran ...... sion in medicare beneficiaries

@en

P2093

Anne L Coleman

http://www.w3.org/2001/XMLSchema#string

Annie M Wu

http://www.w3.org/2001/XMLSchema#string

Connie M Wu

http://www.w3.org/2001/XMLSchema#string

Fei Yu

http://www.w3.org/2001/XMLSchema#string

Flora Lum

http://www.w3.org/2001/XMLSchema#string

Paul B Greenberg

http://www.w3.org/2001/XMLSchema#string

P2860

The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia

Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion.

Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period

Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema.

Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review.

Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.

Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept.

Natural history of central retinal vein occlusion: an evidence-based systematic review.

Physician-Industry Interactions and Anti-Vascular Endothelial Growth Factor Use Among US Ophthalmologists.

P304

105-108

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1016/J.AJOC.2018.06.005

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29998209

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

6038825

http://www.w3.org/2001/XMLSchema#string